The Strategic Case for Outsourcing Cell Culture

Successful drug discovery organizations are constantly making decisions about how to allocate their most valuable resources—scientific talent, laboratory capacity, capital, and time.

The question isn’t simply whether an activity can be performed internally. It’s whether performing it internally is the best use of those resources.

Cell culture outsourcing is a good example. Growing and maintaining cells is essential to many research programs, but it is also labor-intensive and requires dedicated personnel, equipment, laboratory space, quality control, inventory management, and ongoing oversight.

For many research organizations, outsourcing some or all of these activities can provide a more efficient and flexible operating model—while allowing scientists to spend more of their time on the research activities that create the greatest value.

Focus Scientific Talent on High-Value Research

Highly trained scientists are one of the most valuable resources in any R&D organization.

Yet researchers can spend significant amounts of time on routine activities such as thawing cells, expanding cultures, replacing media, counting cells, checking viability, documenting processes, preparing aliquots, and managing cell inventories.

These activities are necessary. But they may not be the activities where an organization’s scientific talent creates the greatest competitive advantage.

Outsourcing routine cell culture activities allows internal scientists to devote more of their time to experimental design, data interpretation, assay development, target validation, drug screening, and other activities that directly advance research programs.

The objective isn’t simply to reduce work. It is to put the right work in the right hands.

Look Beyond the Direct Cost of Cell Culture

Comparing internal and outsourced cell culture solely on the basis of the cost of growing a batch of cells can overlook much of the true cost of maintaining the capability internally.

A more complete analysis should consider the resources required across the entire operation.

Cell Growth and Scale-Up

Internal operations may require:

  • Reagent and media procurement and inventory management
  • Laboratory and equipment preparation
  • Cell thawing and initial testing
  • Multiple cycles of feeding, passage, and scale-up
  • Cell counting and viability testing
  • Documentation throughout the process
  • QC sampling
  • Harvesting, aliquoting, labeling, and controlled freezing
  • Cleanup and equipment maintenance
  • Management, training, troubleshooting, and supervision

There are also ongoing consumable costs associated with media, feed, vials, labels, storage boxes, liquid nitrogen, and other supplies.

Quality Control

Reliable cell culture also requires ongoing quality control.

Depending on the application, this can include batch-specific testing, Mycoplasma testing, cell line authentication, viability assessment, environmental monitoring, equipment checks, documentation, and other QC activities.

Organizations must therefore consider not only the cost of performing the culture itself, but also the infrastructure and expertise required to consistently produce cells that meet research specifications.

Storage and Inventory Management

Cell banks and research inventories must be stored, tracked, retrieved, and maintained over time.

That requires:

  • Freezer and liquid nitrogen storage capacity
  • Inventory management systems
  • Personnel to manage and retrieve samples
  • Backup and monitoring systems
  • Procedures to reduce the risk of lost, misplaced, or compromised samples

These activities may receive relatively little attention when organizations evaluate the cost of maintaining cell culture internally, but they are an important part of the overall operation.

Laboratory Infrastructure and Equipment

An internal cell culture operation can also require substantial dedicated infrastructure, including:

  • Incubators
  • Freezers and refrigerators
  • Laminar flow or biosafety hoods
  • Water baths
  • Cell counters
  • Centrifuges
  • Liquid nitrogen tanks
  • Other analytical and QC equipment

In addition to the initial investment, organizations must account for laboratory space, maintenance, calibration, monitoring, repairs, and eventual equipment replacement.

Reduce Operational Risk

Cell culture carries operational risks as well.

Contamination can compromise an entire batch and potentially affect downstream experiments. Equipment failures can interrupt workflows or jeopardize valuable cell banks. Personnel turnover can create knowledge gaps and require additional training.

A specialized cell culture partner can help distribute these risks by providing established infrastructure, trained personnel, standardized processes, quality systems, and redundant capabilities.

Add Capacity Without Adding Fixed Infrastructure

One of the most important advantages of outsourcing is flexibility.

Research needs rarely remain constant. Programs begin and end. Screening activity increases. New projects enter the pipeline. A large batch may suddenly be required for an important study.

Maintaining enough internal staff and infrastructure to accommodate peak demand can leave resources underutilized during quieter periods.

An outsourcing partner provides another option: access additional capacity when it is needed without permanently expanding internal headcount, equipment, or laboratory space.

This can allow research organizations to:

  • Scale cell production as program requirements change
  • Run multiple projects simultaneously
  • Adjust batch timing based on experimental needs
  • Access additional capacity without lengthy hiring or equipment purchases
  • Reduce bottlenecks when internal laboratories are operating at capacity

Outsourcing therefore becomes more than a cost decision. It can be an important component of a flexible R&D operating model.

Consider the Opportunity Cost

Perhaps the most important cost is also the hardest to see: what could your scientists be doing instead?

Every hour a researcher spends growing cells, managing inventory, troubleshooting equipment, or performing routine preparation is an hour that cannot be spent designing experiments, analyzing results, investigating unexpected findings, or advancing promising therapeutic programs.

For activities that are necessary but not strategically differentiating, outsourcing can create leverage by shifting routine execution to a partner that performs those activities as a core competency.

Choosing What to Keep In-House

Outsourcing cell culture does not have to be an all-or-nothing decision.

Many organizations benefit from a hybrid model in which strategically important or highly specialized activities remain internal while routine, scalable, or resource-intensive activities are handled externally.

The right question is therefore not:

“Should we outsource cell culture?”

It is:

“Which activities should our internal scientists perform, and which can be performed more efficiently by a specialized partner?”

That distinction can help organizations build an R&D model that is more focused, scalable, and efficient.

In some cases, even this can be treated as a relief-valve: When a trusted partner is in place to handle key functions, you can use them (or not) as your own team’s workload fluctuates.

ABS Bio as an Extension of Your Lab

ABS Bio has more than three decades of experience providing custom biological reagents and laboratory services to research organizations.

Our cell culture and related capabilities include:

  • Ready-to-use cells
  • Cell expansion and scale-up
  • Cell banking and cryostorage
  • Cell line identification and quality control
  • DNA and RNA extraction
  • Protein extraction
  • Transfection
  • Cell sorting
  • Flow cytometry, cell QC, and phenotyping
  • Custom cell and tissue preparations

Because these activities are part of our core operations, ABS Bio can provide specialized expertise and infrastructure without requiring clients to build and maintain the same capacity internally.

We work as an extension of your laboratory—providing support when and where you need it while allowing you to retain control over which capabilities remain in-house.

Put Your Resources Where They Create the Most Value

Cell culture is essential to drug discovery. But that doesn’t necessarily mean every cell culture activity needs to be performed by your internal research team.

Well-run R&D organizations continually evaluate where their people, facilities, and capital can generate the greatest return.

For many, outsourcing routine and resource-intensive laboratory activities is one way to create additional capacity, improve operating flexibility, and keep scientists focused on what they do best: research and discovery.

2026-08-07T11:50:25-04:00ABS Blog|

The Role of CROs in Advancing Immuno-Oncology

Immuno-oncology has transformed the landscape of cancer treatment. By harnessing the immune system to recognize and eliminate cancer cells, researchers are unlocking new therapeutic pathways with the potential to improve outcomes across a wide range of tumor types.

But progress in immuno-oncology is complex. It requires specialized expertise, access to high-quality biological materials, and tightly coordinated execution across discovery, translational research, and clinical development.

This is where contract research organizations (CROs) play a critical role.

What CROs Do—and Why They Matter

A Contract Research Organization (CRO) provides outsourced research services to pharmaceutical, biotechnology, and medical device companies. In immuno-oncology, CROs help bridge capability gaps by offering:

  • Scientific expertise
  • Operational infrastructure
  • Scalable resources
  • Regulatory and clinical experience

By leveraging CRO partnerships, biopharma companies can accelerate development timelines, reduce costs, and focus internal teams on core strategic priorities.

How CROs Support Immuno-Oncology Development

Immuno-oncology programs require coordination across multiple, highly specialized domains. CROs support this work across the full development lifecycle.

Discovery and Translational Research

CROs help identify and validate:

  • Novel targets and biomarkers
  • Mechanisms of immune response and resistance
  • Therapeutic candidates and combinations

This early-stage work lays the foundation for successful clinical development.

Biospecimens and Biobanking

Access to high-quality human biospecimens is essential in immuno-oncology.

Biobanking partners support researchers by providing:

  • Ethically sourced, well-characterized human specimens
  • Standardized processing and quality control
  • Access to diverse tumor types and matched samples

ABS Bio supports immuno-oncology research with a comprehensive portfolio of biospecimens, including:

  • Fresh tumor tissues
  • Dissociated tumor cells (DTCs)
  • PBMCs (Peripheral Blood Mononuclear Cells)
  • Advanced models such as 3D histoculture

These materials enable more accurate modeling of tumor biology and immune interactions.

Immunotherapy Development Support

CROs provide capabilities across a range of immunotherapy modalities, including:

  • Monoclonal antibodies
  • Checkpoint inhibitors
  • Cytokine therapies
  • Cancer vaccines
  • Adoptive cell therapies

Support includes analytical development, quality control, and regulatory readiness for complex biologics.

Cell and Gene Therapy (e.g., CAR-T)

For advanced therapies such as CAR-T and other adoptive cell therapies, CROs help manage:

  • Cell engineering and manufacturing workflows
  • Logistics and chain-of-custody requirements
  • Clinical trial design and execution
  • Safety monitoring and regulatory compliance

These therapies are highly personalized and operationally demanding—making experienced partners essential.

The Strategic Value of CRO Partnerships

Beyond execution, CROs provide strategic advantages:

  • Speed: Accelerate timelines from discovery through clinical trials
  • Flexibility: Scale resources up or down as programs evolve
  • Risk reduction: Leverage established processes and expertise
  • Global reach: Enable multi-site clinical trials and regulatory navigation

For immuno-oncology—where timelines, competition, and complexity are high—these advantages are critical.

Collaboration Is the Model Going Forward

Immuno-oncology is not advancing in silos. Success increasingly depends on collaboration across:

  • Biopharmaceutical companies
  • CROs and biobanking partners
  • Academic research institutions
  • Regulatory bodies
  • Patient advocacy groups

CROs play a central role in connecting these stakeholders—helping translate scientific discovery into viable therapies.

How ABS Bio Fits Into the Ecosystem

While CROs provide broad development support, biospecimen quality and availability remain a critical constraint in immuno-oncology research.

ABS Bio focuses on solving this challenge by delivering:

  • High-quality, well-characterized human biospecimens
  • Reliable procurement and processing workflows
  • Access to diverse and clinically relevant sample sets
  • Consistency across studies and sites

By strengthening this foundational layer, ABS Bio enables more reliable data generation—and more confident decision-making in immuno-oncology programs.

Conclusion

Immuno-oncology represents one of the most promising frontiers in cancer research—but also one of the most complex.

CROs play a vital role in advancing this field by providing the expertise, infrastructure, and scalability required to move therapies forward. Within this ecosystem, access to high-quality biospecimens is a critical enabler of success.

Through collaboration between biopharma companies, CROs, and specialized partners like ABS Bio, the pace of innovation in immuno-oncology will continue to accelerate—bringing new therapies to patients faster.

2026-08-06T10:39:53-04:00ABS Blog|

Quality Control: The Backbone of High-Quality Human Biospecimens

In biospecimen research, quality isn’t a feature—it’s the foundation.

Quality control (QC) ensures that biological samples maintain their integrity from collection through processing, storage, and distribution. For researchers, that consistency directly impacts data reliability, reproducibility, and ultimately, the success of downstream studies.

For organizations supporting biopharma and clinical research, QC is not just a technical requirement—it’s a strategic capability.

Why Quality Control Matters

High-quality biospecimens are essential for:

  • Reliable experimental outcomes
  • Reproducible data across studies and sites
  • Regulatory and ethical compliance
  • Confidence from research partners and stakeholders

Without rigorous QC, variability introduced at any stage—collection, handling, or storage—can compromise entire studies.

Quality Management Systems: Turning QC into a Discipline

Effective QC starts with a structured Quality Management System (QMS) that defines:

  • Standardized procedures and protocols
  • Roles and accountability across teams
  • Documentation and traceability
  • Continuous monitoring and improvement

Leading biorepositories align with internationally recognized standards such as:

  • ISO 9001 (Quality Management Systems)
  • ISO 17025 (Testing and calibration laboratories)
  • ISO 15189 (Medical laboratories)
  • ISO/TC 276 (Biotechnology)

A well-implemented QMS does more than ensure compliance—it signals operational maturity and builds trust with partners.

Building an Effective QC Program

A strong QC program goes beyond checklists. It requires a culture of discipline, transparency, and continuous improvement.

Key considerations include:

Continuous Improvement

QC processes must be continuously evaluated and refined based on performance data, audits, and feedback. Organizations that invest in improvement are better positioned to adopt new technologies and scale effectively.

Ethical Responsibility

Biospecimens originate from donors. Maintaining privacy, obtaining informed consent, and safeguarding sample integrity are essential—not optional.

Stakeholder Communication

Clear communication with researchers, regulators, and partners builds trust and ensures expectations around sample quality and handling are aligned.

Future Readiness

QC programs must evolve alongside advances in biotechnology, supporting new research modalities, increased data requirements, and more complex study designs.

The Three Stages of Quality Control

QC in biobanking spans the full lifecycle of a specimen:

1) Pre-Analytical QC

Focuses on everything before processing:

  • Proper labeling and documentation
  • Controlled handling and transport
  • Minimizing variability (e.g., ischemia time, temperature exposure)

Why it matters: Most variability is introduced at this stage.


2) Analytical QC

Applies during processing and storage:

  • Standardized protocols
  • Equipment calibration and validation
  • Environmental monitoring

Why it matters: Ensures consistency across batches, sites, and studies.


3) Post-Analytical QC

Occurs after storage, prior to distribution:

  • Sample quality assessment (e.g., DNA/RNA integrity)
  • Stability and purity checks
  • Ongoing quality assurance and improvement

Why it matters: Confirms the sample meets study requirements before use.

Core QC Procedures in Practice

High-performing biorepositories rely on a combination of structured processes and verification steps:

  • Standard Operating Procedures (SOPs): Ensure consistency across all workflows
  • Training Programs: Align teams on protocols and reduce variability
  • Monitoring & Audits: Identify issues early through inspection and testing
  • Corrective Actions: Rapidly resolve deviations and prevent recurrence

Common validation methods include:

  • Visual inspection for integrity and contamination
  • Cell counts to confirm usability
  • DNA/RNA analysis for identity and purity
  • Biomarker testing to assess sample quality and research relevance

How ABS Bio Approaches Quality

At ABS Bio, quality control is embedded across the entire biospecimen lifecycle—not applied as a final checkpoint.

Our approach emphasizes:

  • End-to-end process control from procurement through delivery
  • Standardized, repeatable workflows designed for consistency
  • Rigorous sample validation aligned with study requirements
  • Operational reliability that researchers can depend on

This integrated model helps ensure that every sample delivered is fit for purpose—supporting more confident decision-making in research and development.

Conclusion

Quality control is not a static process—it’s a continuous commitment.

As research becomes more complex and data expectations increase, the importance of QC will only grow. Organizations that invest in disciplined, well-integrated quality systems are better positioned to deliver reliable biospecimens—and to support meaningful scientific progress.

FAQ

What is quality control in human biospecimen management?
Quality control in biospecimen management refers to the processes used to ensure biological samples maintain their integrity, identity, and usability throughout collection, processing, storage, and distribution.

Why is quality control important for human biospecimens?
Quality control helps ensure reliable research results, reproducible data, regulatory compliance, and confidence in study outcomes.

What are the three stages of biospecimen quality control?
The three stages are pre-analytical quality control, analytical quality control, and post-analytical quality control.

How do biorepositories ensure biospecimen quality?
Biorepositories use standardized operating procedures, staff training, equipment validation, environmental monitoring, audits, and sample testing to maintain quality.

What standards support biospecimen quality management?
Common standards include ISO 9001, ISO 17025, ISO 15189, and ISO/TC 276 biotechnology guidelines.

2026-08-06T10:42:04-04:00ABS Blog|

Ethics of Human Biospecimen Procurement and Distribution

Human biospecimens are essential to advancing biomedical research—but they also carry significant ethical and legal responsibilities.

Behind every sample is a donor. And behind every study is an obligation to ensure that those samples are collected, handled, and used with integrity.

For researchers and sponsors, understanding the ethical framework governing biospecimen procurement is not optional—it’s foundational.

Why Ethics Matter in Biospecimen Research

Ethical biospecimen practices are critical for:

  • Protecting donor rights and privacy
  • Ensuring regulatory compliance
  • Maintaining scientific integrity
  • Building long-term trust across the research ecosystem

Failures in this area don’t just create compliance risk—they can undermine entire research programs.

The Core Ethical Framework

Ethical biospecimen procurement is built on a combination of governance, transparency, and accountability. Several key documents and processes form the foundation.

Informed Consent: The Cornerstone

Informed consent ensures that donors understand—and agree to—how their biological materials will be used.

A robust consent process should clearly explain:

  • How and where samples will be collected
  • How samples will be stored, used, and potentially shared
  • Risks and potential benefits
  • The donor’s rights, including the ability to withdraw consent
  • How privacy and confidentiality are protected

This process reflects a core ethical principle: respect for autonomy

Institutional Review Boards (IRBs): Independent Oversight

Institutional Review Boards (IRBs) are responsible for reviewing and approving research involving human biospecimens.

Their role includes:

  • Evaluating scientific merit and ethical balance
  • Ensuring appropriate consent procedures
  • Protecting donor privacy and welfare
  • Monitoring ongoing compliance

IRBs provide an essential layer of independent oversight—ensuring that research meets both ethical and regulatory standards.

Nondisclosure Agreements (NDAs): Protecting Confidentiality

NDAs are used to safeguard sensitive information, including:

  • Proprietary research data
  • Intellectual property
  • Donor-related information (where applicable)

These agreements define what information is protected, who can access it, and the consequences of misuse.

Material Transfer Agreements (MTAs): Governing Sample Use

Material Transfer Agreements (MTAs) define the terms under which biospecimens are shared between parties.

They typically address:

  • Ownership and permitted use of materials
  • Distribution and sharing restrictions
  • Publication and intellectual property rights
  • Compliance with ethical and regulatory requirements

MTAs are critical for aligning expectations—and avoiding downstream disputes.

Common Questions in Practice

Who owns the data generated from biospecimens?

Ownership is typically defined in the Material Transfer Agreement (MTA).

This agreement outlines:

  • Data ownership rights
  • Publication rights
  • Intellectual property considerations

There is no universal rule—only what is contractually agreed.

Do you need your own IRB to use externally sourced samples?

It depends on the nature of the samples:

  • De-identified samples: May not require additional IRB oversight
  • Identifiable or linked samples: Typically require IRB approval or exemption

Requirements can vary, so alignment with regulatory guidance and institutional policies is essential.

Can samples be shared with third parties?

Only if permitted under the MTA.

Sharing restrictions often include:

  • Limits on redistribution
  • Requirements for additional approvals
  • Obligations to maintain ethical and regulatory compliance

Legal review is strongly recommended before any third-party transfer.

How ABS Bio Approaches Ethics and Compliance

At ABS Bio, ethical procurement is embedded into every stage of the biospecimen lifecycle.

Our approach includes:

  • Strict adherence to informed consent and donor protections
  • Robust governance aligned with IRB and regulatory requirements
  • Clear contractual frameworks (NDAs, MTAs) to define rights and responsibilities
  • End-to-end traceability and documentation

This ensures that every sample is not only high quality—but ethically and legally sound.

Conclusion

Ethics in biospecimen research is not a formality—it’s a prerequisite.

As research becomes more complex and data more valuable, the importance of clear ethical frameworks will only increase. Organizations that prioritize ethical rigor are better positioned to:

  • Protect donors
  • Reduce risk
  • Enable collaboration
  • Deliver credible, defensible science

Ultimately, ethical discipline is what allows innovation to scale responsibly.

Other FAQ

What is ethical human biospecimen procurement?
Ethical human biospecimen procurement involves obtaining biological samples under informed consent, regulatory oversight, and strict donor privacy protections.

Why is informed consent important in biospecimen research?
Informed consent ensures donors understand how their samples may be collected, stored, used, and shared for research purposes.

What role does an IRB play in biospecimen research?
An Institutional Review Board reviews research protocols to ensure donor rights, privacy, and welfare are protected.

What is a Material Transfer Agreement (MTA)?
An MTA defines the legal and ethical terms governing the transfer, use, ownership, and sharing of biospecimens and related data.

2026-08-06T10:42:27-04:00ABS Blog|

Fresh Tumor Tissue vs. Dissociated Tumor Cells: Choosing the Right Biospecimen for Immuno-Oncology R&D

Immuno-oncology research is reshaping how cancer is understood and treated. For the past decade, researchers have been advancing a new generation of therapies with significant clinical promise by leveraging the body’s immune system to target tumors.

In this work, the quality and type of biological material matter. Two commonly used approaches, fresh tumor tissue and dissociated tumor cells (DTCs), offer distinct advantages depending on the research objective.

This article outlines the strengths and limitations of each, and how ABS Bio supports researchers with high-quality, fit-for-purpose specimens.

Fresh Tumor Tissue: Preserving the Tumor Microenvironment

Fresh tumor tissue provides close ex-vivo representation of the tumor in its native state, including epithelial structures, stromal components and immune cell infiltration (TILs). This makes it especially valuable for studies focused on tumor–immune system interactions.

Advantages

  • Microenvironment integrity: Maintains spatial relationships between tumor, blood vessels, stromal, and immune cells
  • Tumor heterogeneity: Enables analysis across different regions of the same tumor
  • Ex vivo applications: Supports tissue culture models, including 3D histoculture, and downstream cell line development

Considerations

  • Limited viability window: Sample integrity can decline rapidly post-resection (usually 36-48 hours)
  • Logistical complexity: Collection, handling, and transport require tight coordination
  • Stromal interference: Can complicate isolation and analysis of specific immune populations

Dissociated Tumor Cells (DTCs): Standardization and Scalability

DTCs are prepared shortly after resection, creating a representative population of tumor cells suitable for controlled, high-throughput studies.

Advantages

  • Extended usability: Cryopreservation enables longer-term storage and broader distribution
  • Scalability: Cells can be expanded for larger studies and screening programs
  • Matched samples: Can be paired with patient-matched PBMCs for immunological analysis and FFPE samples for IHC and genomic studies

Considerations

  • Loss of context: Dissociation disrupts the native tumor architecture
  • Underrepresentation of rare cells: Some immune populations may not be captured
  • Selection bias: Processing may favor certain subpopulations

Comparing Research Applications

 

Research Accuracy

  • Fresh tissue: Best suited for studying tumor architecture, heterogeneity, and immune interactions
  • DTCs: Ideal for controlled experiments, repeatability, and large-scale screening

Clinical Relevance

  • Fresh tissue: Remains the gold standard for pathology and biomarker identification
  • DTCs: Useful for long-term storage, longitudinal studies and assay development, though with more limited clinical context

Applications in Immunology Research

Fresh Tumor Tissue

  • Characterizing immune cell activation and infiltration within the tumor microenvironment
  • Identifying tumor-associated antigens
  • Evaluating checkpoint marker expression and immune evasion mechanisms

DTCs

  • Detecting tumor-specific antigens for therapeutic targeting
  • Monitoring post-treatment immune response
  • Supporting biomarker discovery and assay development

Choosing the Right Approach

The optimal material depends on the research goal:

  • Tumor microenvironment studies → Fresh tumor tissue
  • Drug candidates MOA and efficacy→ Fresh tumor 3D histoculture
  • High-throughput screening or longitudinal studies → DTCs
  • Metastasis and liquid biopsy research → DTCs

In many cases, a combined approach delivers the most comprehensive insight.

How ABS Bio Supports Immuno-Oncology R&D

ABS Bio provides access to both fresh tumor tissue and dissociated tumor cells through a globally integrated network and rigorously controlled processes.

Our approach is designed to deliver:

  • High-quality, viable specimens with tightly managed collection and processing timelines
  • Operational reliability across procurement, logistics, and downstream handling
  • Broad access to tumor types and matched samples through an established partner network
  • Flexible formats to support both microenvironment-focused and high-throughput workflows

By aligning specimen type with study design and ensuring consistent quality at every step ABS Bio helps researchers generate more reliable, actionable data.

Conclusion

Both fresh tumor tissue and DTCs play essential roles in advancing immuno-oncology research. Each offers distinct strengths, and the right choice depends on the scientific question at hand.

With the right sourcing strategy and operational support, researchers can leverage both approaches to better understand tumor biology and accelerate the development of next-generation immunotherapies.

FAQ

What quantity of fresh tumor tissue is typically available?

Most surgical resections yield approximately 200–500 mg of tissue, depending on tumor type and procedure.

How are DTCs collected?

DTCs are isolated shortly after resection using standardized processing protocols. ABS Bio can provide guidance based on study needs.

How is tissue viability maintained during transport?

Fresh tissues are shipped in optimized media (e.g., HypoThermosol or DMEM) at controlled temperatures (4–6°C) with validated logistics protocols.

2026-08-06T10:42:53-04:00ABS Blog|

Seven Questions Drug Discovery Teams Should Ask Before Choosing a Biospecimen Provider

For drug discovery and translational research teams, selecting a reliable biospecimen provider is a strategic decision that directly affects data quality, study reproducibility, and program timelines.

High-quality human biospecimens—paired with robust clinical data and consistent processing—can accelerate target validation, biomarker development, and therapeutic insights. Conversely, poor-quality or poorly annotated specimens introduce unnecessary risk and delay.

To support better decision-making, here are seven consultative questions that can help you assess whether a potential biospecimen partner is equipped to meet the scientific and operational needs of your research.


1. What Is the Source of the Human Biospecimens?
A provider’s sourcing framework is fundamental to specimen relevance. Clarifying whether samples originate from patient donors, healthy volunteers, or established cell lines helps determine suitability for your specific disease model or translational study.

For drug discovery applications, patient-derived biospecimens often offer the highest scientific value because they reflect real-world biological variability. Understanding sourcing channels also helps you anticipate feasibility, diversity of supply, and sample availability.


2. What Clinical and Pathological Data Accompany the Biospecimens?
High-quality biospecimens must be paired with accurate, well-structured metadata. Ask what clinical, pathological, and demographic information is available—including diagnosis details, treatment history, comorbidities, staging, and relevant lab values.

Rich annotation supports better cohort design, deeper biomarker exploration, and more precise correlation analyses. When evaluating providers, prioritize those who can deliver consistent, reliable data packages—not just samples.


3. How Are Specimens Collected, Processed, and Preserved?
Pre-analytical variation remains one of the largest sources of experimental noise. Understanding a provider’s SOPs for collection, handling, and storage is crucial.

Key areas to clarify include:

  • Informed consent and IRB compliance
  • Timing and methods of collection
  • Processing workflows (e.g., centrifugation, aliquoting, FFPE handling)
  • Cryopreservation and storage conditions

Providers with standardized, validated procedures significantly reduce risk and ensure your biospecimens perform as expected in downstream assays.


4. What Quality Control Measures Support Sample Integrity?
Quality control is central to biospecimen reliability. Ask about identity verification, viability assessments, contamination screening, and documentation of chain-of-custody.

Providers with robust QC programs can demonstrate how they maintain specimen integrity from collection through shipment. Clear QC practices not only protect your research but also support reproducibility across internal and external stakeholders.


5. Are the Biospecimens Ethically Sourced and Fully Compliant?
Regulatory and ethical compliance is essential for any organization handling human materials. Confirm the provider meets requirements related to:

  • Informed consent
  • HIPAA, GDPR, and GCP compliance
  • Ethical review and documentation
  • Data privacy safeguards

A transparent compliance program reduces legal and operational risk and streamlines your internal review processes.


6. Can the Provider Share References or Case Studies?
Reputable providers should be able to demonstrate their track record supporting drug discovery, translational research, and biomarker development.

Case studies, references, or examples of prior collaborations offer insight into their reliability, scientific alignment, and experience with complex or highly customized projects. These indicators help you evaluate whether the partner can scale with your research needs.


7. What Logistics, Lead Times, and Cost Models Should You Expect?
Timely access to biospecimens is essential for maintaining program momentum. Ask about expected lead times for prospective collections, current inventory availability, shipping methods, packaging standards, and pricing structures.

Providers who offer clear communication, predictable timelines, and transparent costs make it easier to forecast resources and prevent downstream bottlenecks.


Why These Questions Matter

A strong biospecimen provider should function as more than a vendor—they should operate as an extension of your scientific team. By evaluating partners with these seven questions, drug discovery groups can ensure access to the high-quality biospecimens and reliable data needed to confidently advance programs.

At ABS Bio, we take a consultative approach to supporting drug discovery and translational scientists. Our team collaborates closely with clients to understand project goals, identify the right sourcing strategies, and deliver specimens backed by rigorous quality systems and ethical standards.

With a diverse portfolio of human biospecimens and decades of operational expertise, we help research teams reduce risk and keep their programs moving forward with confidence.

2026-08-03T11:18:15-04:00ABS Blog|

Why Biospecimen Procurement Shouldn’t Be a “One-Click” Process

Why Biospecimen Procurement Shouldn’t Be a “One-Click” Process

At ABS Bio, our mission is simple: make it easy to get the high-quality human biospecimens you need to advance your research.

At first glance, it might seem like a web store or online marketplace could accomplish this. After all, similar platforms already exist. Wouldn’t that make the process faster and cheaper?

In theory—yes. But in practice, human biospecimens are not commodities. Unlike computers or lab equipment, each sample represents a unique human donor, with biological and contextual variables that directly affect your data integrity and study outcomes.


Why “One-Size-Fits-All” Doesn’t Work for Biospecimens

When you buy a laptop online, you configure your system from fixed variables, add it to your cart, pay and then receive exactly what you expect.

Biospecimens don’t work that way.

Each donor differs by:

  • Demographics (age, sex, race)
  • Medical and treatment history
  • Medications and comorbidities
  • Collection methods and site practices

These differences matter. A variable such as collection timing, preservation technique, or pathology reporting can make or break the suitability of a specimen for your research.

Even cost structures vary between collection sites—so any “flat” pricing model would have to be artificially inflated to cover every scenario.


The Variables That Matter

When sourcing biospecimens, experienced researchers know that every project has its own parameters.

Here are just some of the factors that must be considered:

Category Example Variables
Ethical & Regulatory Informed consent scope, IRB review, country-specific regulations
Donor Profile Age, sex, race, diagnosis, treatment history
Collection & Preservation Time to preservation, fixatives, storage conditions
Pathology & Data Full or partial pathology reports, histology, gene expression data
Medical & Medication History Specific conditions, drug exposure, duration
Sample Specifications Tumor percentage, necrosis, preservation type, sample size
Quality Control RIN values, histology verification, IHC testing
Pricing Customized for prospective or retrospective collections
Logistics & Shipping How much do you need, when do you need it, temperature excursions during shipping, communication about package progress

Each of these elements influences sample quality, study relevance, and reproducibility.


The Case for a Consultative Approach

Rather than offering a “shopping cart” experience, ABS Bio takes a collaborative, consultative approach.

Our biospecimen experts work directly with you to:

  1. Define your scientific and budgetary requirements
  2. Identify suitable collection sites and ethical parameters
  3. Customize collection and processing methods
  4. Ensure that quality control measures align with your study’s goals
  5. Deliver samples that are truly fit for purpose and on-time

This process doesn’t slow you down—it prevents wasted time, effort, and expense on unsuitable material.


Avoiding the Pitfalls of Commoditization

Marketplaces encourage “good enough” thinking.

They make it easy to overlook variables that could impact your findings—or miss opportunities to design collections that support both your current study and future research.

By contrast, our model promotes:

  • Creative problem-solving for challenging requests
  • Access to a wide network of qualified collection sites
  • Transparency and flexibility around pricing, QC, and turnaround time

Our Commitment to You

ABS Bio exists to provide the right samples, not just available samples.

We’ll work with you to clarify your needs, source from the best-suited sites, and ensure that every specimen supports the integrity of your research.

That’s why we continue to focus on customizable, scientist-driven solutions—not a one-click marketplace.

The fastest way to get what you truly need? Talk with our team.

We’ll make sure your biospecimen strategy supports your science today—and sets you up for success tomorrow.

2026-08-03T11:18:15-04:00ABS Blog|

Human Biospecimen Quality Considerations in Biomedical Research

Human biospecimens—such as blood, tissue, urine, and saliva—are fundamental to biomedical research, serving as the cornerstone for studies investigating disease mechanisms, treatment efficacy, and genetic predispositions.

However, the utility of these biospecimens depends heavily on their quality, as variations in sample collection, handling, storage, and processing can introduce biases that compromise the reliability of research outcomes.

Therefore, maintaining the highest standards for biospecimen quality is crucial for obtaining valid results. This article explores key considerations for ensuring the quality of human biospecimens in research settings.

1. Pre-Analytical Factors: Collection and Handling
The first step in preserving biospecimen quality begins at the point of collection. Factors such as the timing, collection method, and conditions under which samples are obtained can significantly influence their integrity. For example, blood samples should be collected by qualified professionals using proper tools and anticoagulants, followed by immediate processing and preservation to avoid degradation of biomolecules like RNA or proteins. Similarly, tissue samples must be quickly frozen or fixed to preserve cellular structures and prevent enzymatic activity that can degrade the sample.

Sample contamination during collection is another major concern. Strict protocols must be followed to avoid cross-contamination between specimens, donors, and environmental sources. Researchers should ensure the use of sterile equipment and proper personal protective equipment (PPE) during sample collection and handling to minimize such risks.

2. Storage and Transportation
Once biospecimens are collected, their storage conditions become pivotal in maintaining their quality. Biological samples are often sensitive to temperature, light, and other environmental factors, which can result in the degradation of DNA, RNA, proteins, and other molecular entities. For instance, blood samples are typically processed into plasma or serum and stored at -80°C to maintain stability for downstream analyses. Similarly, tissue samples need to be either fixed in formalin or frozen immediately upon collection.

The transportation of biospecimens to research labs must also be carefully controlled. Samples should be transported in validated containers that maintain the appropriate temperature and humidity levels and ensure the sample integrity during transit. If samples are transported over long distances, the use of specialized freight carriers or dry ice may be necessary to ensure that they remain within the required conditions to prevent degradation.

3. Quality Control and Standardization
Standardized protocols for biospecimen collection, processing, and storage are essential to ensure consistency across different studies and institutions. The establishment of clear guidelines and standard operating procedures (SOPs) helps minimize variability in sample quality. Quality control (QC) procedures are also critical to verify the integrity of biospecimens before use in research. For example, DNA and RNA quantification, as well as assessments of integrity (e.g., gel electrophoresis for RNA quality), are common QC measures to ensure that the specimens meet the necessary criteria for analysis.

Additionally, biomarker stability can vary depending on the specific assay or research question. Researchers must take into account how their chosen biomarkers behave in different sample types and storage conditions. The use of reference materials and biospecimen validation ensures the reliability of results across multiple labs and study populations.

4. Ethical and Regulatory Considerations
Ethical issues related to the use of human biospecimens are also central to quality. Informed consent from donors must be obtained, and biospecimens should be handled in accordance with local ethical guidelines and regulations. The use of biospecimens is often governed by institutional review boards (IRBs) or ethics committees to ensure that research adheres to the principles of ethical research conduct, including privacy protection and donor anonymity.

Conclusion
Ensuring the quality of human biospecimens is a multifaceted process that requires attention to detail at every stage—from collection and handling to storage, transport, and analysis. By adhering to standardized protocols, maintaining stringent quality control measures, and addressing ethical concerns, researchers can optimize the use of biospecimens in biomedical studies, ultimately leading to more reliable, reproducible, and impactful scientific discoveries.

2026-08-03T11:18:15-04:00ABS Blog|

Cell Culture Outsourcing in Difficult Markets?

During unsettled economic times, drug developers must deal with elevated levels of uncertainty when allocating their precious research resources. As pressure grows to reduce overhead and streamline operations, managers must make hard choices about which tasks are truly core. With manpower limited, or even reduced, how can departments continue to push forward in achieving their research objectives?

(more…)

2026-08-03T11:18:16-04:00ABS Blog|

Is Outsourced Biospecimen Procurement Right for Your Drug Discovery Team?

Access to high-quality human biospecimens is a critical part of early-stage drug discovery—fueling everything from target validation to biomarker discovery. But sourcing these samples in-house can be slow, complex, and risky. So how do you know if outsourcing is the right move?

Ask yourself these questions…

1. Do we have the right networks to access high-quality samples?
Building and maintaining relationships with hospitals, biobanks, and clinical sites takes time and trust. If your team lacks access to diverse, well-annotated biospecimens, a specialized sourcing partner can bridge the gap.

2. Do we have the infrastructure in place to optimize the regulatory and ethical requirements??
Navigating IRB approvals, consent documentation, and data privacy regulations (like HIPAA and GDPR) can be time-consuming. Outsourcing to a provider with established compliance infrastructure can accelerate timelines and reduce legal risk.

3. Can we verify sample quality and metadata?
Poor sample quality leads to wasted time and unreliable data. Reputable suppliers implement standardized collection protocols, track pre-analytical variables, and provide rich clinical annotations—giving you confidence in your results.

4. Is our team spending too much time managing logistics?
Coordinating shipments, managing cold chain requirements, and troubleshooting delays aren’t the best use of scientific talent. Outsourcing frees up your team to focus on analysis and discovery rather than procurement and paperwork.

5. Do we need a diversified population of donors and samples?
If your research targets common, easily accessible populations, rare diseases, treatment-naïve populations, or matched sample sets, a specialized biospecimen provider is more likely to deliver what you need—quickly and ethically.

The Bottom Line
Outsourcing the procurement of biospecimens with reputable suppliers isn’t about giving up control—it’s about gaining speed, consistency, and compliance. By answering these questions, your drug discovery team can make a strategic decision that keeps the science moving forward.

2026-08-03T11:18:16-04:00ABS Blog|
Go to Top